Hamburg, Germany - 04 September 2015: Evotec AG today published its updated DDup Special edition “Drug discovery services”. This new edition outlines Evotec’s drug discovery platforms including new capacities, capabilities and expertise from its recently established sites in Princeton, USA, and Toulouse, France.
Evotec’s DDup Special Edition highlights the broad range of the Company’s activities from target identification to pre-clinical candidate, supported by state-of-the-art technology platforms and highly experienced scientists in various therapeutic areas including neuroscience, metabolic diseases, oncology, pain, inflammation and infectious diseases. Evotec aims to deliver an industrialised, cutting-edge, comprehensive and unbiased drug discovery infrastructure to support its partners’ needs through stand-alone services or as part of fully integrated solutions.